Anidulafungin

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Candidemia

Conditions

Candidemia

Trial Timeline

Jan 1, 2008 → Mar 1, 2009

NCT ID

NCT00537329

About Anidulafungin

Anidulafungin is a phase 3 stage product being developed by Pfizer for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00537329. Target conditions include Candidemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01202253	Pre-clinical	Completed	Feb 1, 2011	May 1, 2011	Candidiasis
NCT00934934	Phase 2	Terminated	Apr 1, 2010	Aug 1, 2012	Ventilator Associated Pneumonia
NCT01053884	Phase 2	Terminated	Oct 1, 2009	Sep 1, 2011	Hematologic Malignancies
NCT00537329	Phase 3	Completed	Jan 1, 2008	Mar 1, 2009	Candidemia
NCT00056381	Phase 1/2	Completed	Jul 1, 2003	Jun 1, 2004	Neutropenia

Competing Products

9 competing products in Candidemia

See all competitors

Product	Company	Stage	Hype Score
micafungin + Micafungin + Caspofungin	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Approved	85
AmBisome	Gilead Sciences	Approved	84
Anidulafungin/Fluconazole	Pfizer	Phase 3	76
Anidulafungin + Voriconazole	Pfizer	Approved	84
Anidulafungin + Fluconazole	Pfizer	Phase 3	76
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo	Basilea Pharmaceutica	Phase 3	72
APX001	Basilea Pharmaceutica	Phase 2	47
APX001	Basilea Pharmaceutica	Phase 2	47

Other Products from Pfizer